CoChat
Sign Up
Cited by 46Advanced Glycation End Products researchPsoriasis: Treatment and PathogenesisSkin Diseases and Diabetes

Advanced Glycation End Products are Increased in the Skin and Blood of Patients with Severe Psoriasis

Open access
Papagrigoraki, A, Giglio, M, Cosma, C, Maurelli, M, Girolomoni, G, Lapolla, A·2017·Acta Dermato Venereologica
DOI 10.2340/00015555-2661
Open this paper in CoChat — free accountOpen PDF

Abstract

Psoriasis is frequently associated with metabolic comorbidities. Advanced glycation end products (AGEs) are highly oxidant, biologically active compounds that accumulate in tissues in association with hyperglycaemia, hyperlipidaemia and oxidative stress. This is a cross-sectional case-control study involving 80 patients with mild/severe psoriasis and 80 controls matched for age, sex and body mass index (40 with severe eczema, 40 healthy individuals). Patients and healthy individuals with a smoking habit, diabetes, dyslipidaemia, hypercholesterolaemia, hypertension or who were under systemic treatment were excluded from the study. Skin AGEs were measured in normal-appearing skin by a standard fluorescence technique, and blood AGEs (total AGEs, pentosidine and AGEs receptor) by enzyme-linked immunosorbent assay. Levels of cutaneous AGEs (p < 0.04), serum AGEs (p < 0.03) and pentosidine (p <0.05) were higher in patients with severe psoriasis. Cutaneous AGEs correlated well with serum AGEs (r = 0.93, p < 0.0001) and with Psoriasis Area and Severity Index score (r = 0.91, p < 0.0001). Receptor levels were lower (p < 0.001) in severe psoriasis, and inversely correlated with disease severity (r = -0.71, p < 0.0002). Patients with severe psoriasis have accumulation of skin and serum AGEs, independent of associated metabolic disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2340/00015555-2661

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Pentosidine levels were higher in psoriasis patients than in healthy individuals (n = 40 per group).

    “| Psoriasis | Skin, serum | Healthy individuals and psoriasis patients (n = 40 per group) | Skin AF,ELISA | Higher skin AF, total AGEs and pentosidine levels in patients with psoriasis | [239] |”

    From Protein oxidation - Formation mechanisms, detection and relevance as biomarkers in human diseases (2021) · cites this paper as [239]

    The Results report significantly higher serum pentosidine in patients with severe psoriasis than in healthy subjects (p < 0.0001). The study included 40 people in each of those groups (Results, Table I). The finding is specific to severe psoriasis; the claim's unqualified reference to psoriasis patients could also include the mild-psoriasis group, for which this comparison is not reported. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • Total AGE levels were higher in psoriasis patients than in healthy individuals (n = 40 per group).

    “| Psoriasis | Skin, serum | Healthy individuals and psoriasis patients (n = 40 per group) | Skin AF,ELISA | Higher skin AF, total AGEs and pentosidine levels in patients with psoriasis | [239] |”

    From Protein oxidation - Formation mechanisms, detection and relevance as biomarkers in human diseases (2021) · cites this paper as [239]

    Table II (Discussion) reports higher total serum AGEs in the 40 patients with severe psoriasis than in the 40 healthy individuals. The claim omits the severity qualifier: the paper also studied 40 patients with mild psoriasis, whose mean total AGE level was lower than that of healthy individuals. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • Skin autofluorescence was higher in psoriasis patients than in healthy individuals (n = 40 per group).

    “| Psoriasis | Skin, serum | Healthy individuals and psoriasis patients (n = 40 per group) | Skin AF,ELISA | Higher skin AF, total AGEs and pentosidine levels in patients with psoriasis | [239] |”

    From Protein oxidation - Formation mechanisms, detection and relevance as biomarkers in human diseases (2021) · cites this paper as [239]

    The Results report higher skin AGE fluorescence in 40 patients with severe psoriasis than in 40 healthy controls (2.87 versus 1.86; p = 0.01). The study also included 40 patients with mild psoriasis, but the cited comparison does not establish the same finding for psoriasis patients generally. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 43

  1. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-385.
  2. Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin 2015; 33: 41-55.
  3. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart As- soc 2013; 42: e000062.
  4. Miller IM, Skaaby T, Ellervik C, Jemec GBE. Quantifying car- diovascular disease risk factors in patients with psoriasis: a meta-analysis. Br J Dermatol 2013; 169: 1180-1187.
  5. Kölliker Frers RA, Bisoendial RJ, Montoya SF, Kerzkerg E, Castilla R, Tak PP, et al. Psoriasis and cardiovascular risk: immune-mediated crosstalk between metabolic, vascular and autoimmune inflammation. IJC Metabol Endocrine 2015; 6: 43-54.
  6. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of car- diovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31: 1000-1006.
  7. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Pese- rico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
  8. Puig L, Strohal R, Husni ME, Tsai TF, Noppakun N, Szumski A, et al. Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to- severe psoriasis and psoriatic arthritis. J Dermatolog Treat 2015; 26: 7-15.
  9. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end- products: a review. Diabetologia 2001; 44: 129-146.
  10. Pizzimenti S, Ciamporcero E, Daga M, Pettazzoni P, Arcaro A, Cetrangolo G, et al. Interaction of aldehydes derived from lipid peroxidation and membrane proteins. Front Physiol 2013; 4: 242.
  11. Lapolla A, Reitano R, Baccarin L, Sartore G, Plebani M, Fedele D. Pentosidine plasma levels and relation with metabolic con- trol in diabetic patients. Horm Metab Res 2005; 37: 252-256.
  12. Peppa M, Vlassara. Advanced glycation end products and diabetic complications: a general overview. H. Hormones (Athens) 2005; 4: 28-37.
  13. Piarulli F, Sartore G, Lapolla A. Glyco-oxidation and cardio- vascular complications in type 2 diabetes: a clinical update. Acta Diabetol 2013; 50: 101-110.
  14. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all- cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 2011; 34: 442-447.
  15. Jaisson S, Gillery P. Evaluation of nonenzymatic posttrans- lational modification-derived products as biomarkers of mo- lecular aging of proteins. Clin Chem 2010; 56: 1401-1412.
  16. Sayej WN, Knight Iii PR, Guo WA, Mullan B, Ohtake PJ, Da- vidson BA, et al. Advanced glycation end products induce obesity and hepatosteatosis in CD-1 wild-type mice. Biomed Res Int 2016; 2016: 7867852.
  17. Clarke RE, Dordevic AL, Tan SM, Ryan L, Coughlan MT. Dietary advanced glycation end products and risk factors for chronic disease: a systematic review of randomised controlled trials. Nutrients 2016; 8: E125.
  18. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, et al. RAGE (receptor for advanced glycation end products), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009; 7: 1-27.
  19. Colhoun HM, Betteridge DJ, Durrington P, Hitman G, Neil A, Livingstone S, et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes. Diabetes 2011; 60: 2379-2385.
  20. Kim JK, Park S, Lee MJ, Song YR, Han SH, Kim SG, et al. Plasma levels of soluble receptors for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN- RAGE) are associated with carotis atherosclerosis in patients with peritoneal dialysis. Atherosclerosis 2012; 220: 208-214.
  21. Langley RG, Ellis GN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51: 563-569.
  22. Sugarman JL, Fluhr JW, Fowler AJ, Bruckner T, Diepgen TL, Williams ML. The objective severity assessment of atopic dermatitis score: an objective measure using permeabi- lity barrier function and stratum corneum hydration with computer-assisted estimates for extent of disease. Arch Dermatol 2003; 139: 1417-1422.
  23. Chen DY, Chen YM, Lin CC, Hsieh CW, Wu YC, Hung WT, et al The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the patho genesis of adult-onset still's disease. BMC Musculoskelet Disord 2015; 16: 111.
  24. Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010; 110: 911-916.
  25. Sharma C, Kaur A, Thind SS, Singh B, Raina S. Advanced glycation end-products (AGEs): an emerging concern for processed food industries. J Food Sci Technol 2015; 52: 7561-7576.
  26. Barrea L, Balato N, Di Somma C, Macchia PE, Napolitano M, Savanelli MC, et al. Nutrition and psoriasis: is there any as- sociation between the severity of the disease and adherence to the Mediterranean diet? J Transl Med 2015; 13: 18.
  27. Crisan M, Taulescu M, Crisan D, Cosgarea R, Parvu A, Cãtoi C, et al. Expression of advanced glycation end-products on sun-exposed and non-exposed cutaneous sites during the ageing process in humans. PLoS One 2013; 8: e75003.
  28. Jiao L, Taylor PR, Weinstein SJ, Graubard BI, Virtamo J, Albanes D, et al. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 1430-1438.
  29. Bergmann C, Strohbuecker L, Lotfi R, Sucker A, Joosten I, Koenen H, et al. High mobility group box 1 is increased in the sera of psoriatic patients with disease progression. J Eur Acad Dermatol Venereol 2016; 30: 435-441.
  30. Soboleva AG, Bruskin SA, Nikolaev AA, Sobolev VV, Me- zentsev AV. Role of receptor for advanced glycation end- products in pathogenesis of psoriasis. Mol Biol (Mosk) 2013; 47: 743-753.
  31. Mezentsev AV, Bruskin SA, Soboleva AG, Sobolev VV, Piruzian ES. Pharmacological control of receptor of advanced glyca- tion end-products and its biological effects in psoriasis. Int J Biomed Sci 2013; 9: 112-122.
  32. Shubbar E, Vegfors J, Carlström M, Petersson S, Enerbäck C. Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation. Breast Cancer Res Treat 2012; 134: 71-80.
  33. Al Rifai M, Schneider AL, Alonso A, Maruthur N, Parrinello CM, Astor BC, et al. sRAGE, inflammation, and risk of atrial fibril- lation: results from the Atherosclerosis Risk in Communities (ARIC) study. J Diabetes Complications 2015; 29: 180-185.
  34. Ono S, Tanizaki H, Otsuka A, Endo Y, Koyanagi I, Kataoka TR, et al. Coexistent skin lesions of vitiligo and psoriasis vul- garis. Immunohistochemical analyses for IL-17A-producing cells and regulatory T cells. Acta Derm Venereol 2014; 94: 329-330.
  35. Damasiewicz-Bodzek A, Wielkoszyński T. Advanced glyca- tion in psoriasis. J Eur Acad Dermatol Venereol 2012; 26: 172-179.
  36. Johansen C, Bertelsen T, Ljungberg C, Mose M, Iversen L. Characterization of TNF-α-and IL-17A-mediated synergistic induction of DEFB4 gene expression in human keratinocytes through IκBζ. J Invest Dermatol 2016; 136: 1608-1616.
  37. Lohwasser C, Neureiter D, Weigle B, Kirchner T, Schuppan D. The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glyca- tion end products and tumor necrosis factor-alpha. J Invest Dermatol 2006; 126: 291-299.
  38. Masouri S, Stefanaki I, Ntritsos G, Kypreou KP, Drakaki E, Evangelou E, et al. A pharmacogenetic study of psoriasis risk variants in a greek population and prediction of responses to anti-TNF-α and anti-IL-12/23 agents. Mol Diagn Ther 2016; 20: 221-225.
  39. Kaur S, Zilmer K, Leping V, Zilmer M. Serum methylglyoxal level and its association with oxidative stress and disease severity in patients with psoriasis. Arch Dermatol Res 2013; 305: 489-494.
  40. Heo YJ, Oh HJ, Jung YO, Cho ML, Lee SY, Yu JG, et al. The ex- pression of the receptor for advanced glycation end-products (RAGE) in RA-FLS is induced by IL-17 via Act-1. Arthritis Res Ther 2011; 13: 113.
  41. Batycka-Baran A, Hattinger E, Zwicker S, Summer B, Zack Howard OM, Thomas P, et al. Leucocyte derived koebnerisin (S100A15) and psoriasin (S100A7) are systemic mediators of inflammation in psoriasis. J Dermatol Sci 2015; 79: 214-221.
  42. Vasků V, Kanková K, Vasků A, Muzík J, Izakovicová Hollá L, Semrádová V, et al. Gene polymorphisms (G82S, 1704G/T, 2184A/G and 2245G/A) of the receptor of advanced glycation end products (RAGE) in plaque psoriasis. Arch Dermatol Res 2002; 294: 127-130.
  43. Manigrasso MB, Pan J, Rai V, Zhang J, Reverdatto S, Quadri N, et al. Small molecule inhibition of ligand-stimulated RAGE-DIAPH1 signal transduction. Sci Rep 2016; 6: 22450.

Cited by

Sorted by citations

Authors
Papagrigoraki, A., Giglio, M., Cosma, C., Maurelli, M., Girolomoni, G., & Lapolla, A.
Affiliations
  • University of Verona (IT)
  • University of Padua (IT)
ORCID
Venue
Acta Dermato Venereologica
Publisher
Medical Journals Sweden AB
Published
2017
Volume
97
Issue
7
Pages
782-787
ISSN
0001-5555 (ISSN-L)
DOI
10.2340/00015555-2661
OpenAlex
W2598221376
Cited by
46
References
1
Citations by year
2026: 5 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 6 · 2021: 7 · 2020: 3 · 2019: 4 · 2018: 3 · 2017: 4
FWCI
3.18
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Acta Dermato Venereologica (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • INFM-OAR (INFN Catania) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Padua Research Archive (University of Padova) (submittedVersion, cc-by)
  • Zenodo (CERN European Organization for Nuclear Research) (cc-by)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Health Sciences › Medicine › Dermatology › Skin Diseases and Diabetes
Keywords
advanced glycation end products, psoriasis, severe psoriasis, pentosidine, AGE receptor, serum AGEs, oxidative stress, disease severity, Psoriasis Area and Severity Index, metabolic comorbidities
MeSH terms
Adult, Cross-Sectional Studies, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Psoriasis, Severity of Illness Index, Skin, Spectrometry, Fluorescence, Biomarkers, Up-Regulation, Case-Control Studies, Glycation End Products, Advanced

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review